Kelly Doyle
No Rating Available
(Learn About Our Rating System)

Kelly Doyle, PhD, DABCC, FAACC

Languages spoken: Portuguese, Spanish, English

Dr. Kelly Doyle is a fellow in the National Academy of Clinical Biochemistry and is a board certified clinical chemist. His interests involve the clinical application and implementation of mass spectrometry, emerging biomarkers, toxicology, endocrinology, and laboratory best practice. He has a special interest in training clinical chemistry fellows and teaching principles of laboratory medicine to pathology residents and medical students.

Specialties

  • Pathology, Clinical

Board Certification

American Board of Clinical Chemistry

Dr. Kelly Doyle is a fellow in the National Academy of Clinical Biochemistry and is a board certified clinical chemist. His interests involve the clinical application and implementation of mass spectrometry, emerging biomarkers, toxicology, endocrinology, and laboratory best practice. He has a special interest in training clinical chemistry fellows and teaching principles of laboratory medicine to pathology residents and medical students.

Board Certification and Academic Information

Academic Departments Pathology -Associate Professor (Clinical)
Board Certification
American Board of Clinical Chemistry

Education history

Undergraduate Chemistry - Utah State University B.S.
Doctoral Training Medicinal Chemistry - University of Utah Ph.D.
Research Fellow Oncology and Medicinal Chemistry - Huntsman Cancer Institute, Center for Investigational Therapeutics Postdoctoral Research Fellow
Fellowship Clinical Chemistry - University of Utah School of Medicine Fellow

Selected Publications

Journal Article

  1. Doyle K, Frank EL (2021). Verifying Clinically Derived Reference Intervals for Daily Excretion Rates of Fractionated Metanephrines Using Modern Indirect Reference Interval Models. Am J Clin Pathol, 156(4), 691-699.
  2. Cordray P, Doyle K, Edes K, Moos PJ, Fitzpatrick FA (2007). Oxidation of 2-Cys-peroxiredoxins by arachidonic acid peroxide metabolites of lipoxygenases and cyclooxygenase-2. J Biol Chem, 282(45), 32623-9.
  3. Doyle K, Fitzpatrick FA (2010). Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function. J Biol Chem, 285(23), 17417-24.
  4. Marin SJ, Doyle K, Chang A, Concheiro-Guisan M, Huestis MA, Johnson-Davis KL (2016). One Hundred False-Positive Amphetamine Specimens Characterized by Liquid Chromatography Time-of-Flight Mass Spectrometry. J Anal Toxicol, 40(1), 37-42.
  5. Bahr TM, Christensen RD, Ward DM, Meng F, Jackson LK, Doyle K, Christensen DR, Harvey AG, Yaish H (2019). Ferritin in serum and urine: A pilot study. Blood cells, molecules & diseases, 76, 59-62.
  6. c. Althaus, T., Lubell, Y., Maro, V. P., Mmbaga, B. T., Lwezaula, B., Halleux, C., Biggs, H. M., Galloway, R. L., Stoddard, R. A., Perniciaro, J. L., Nicholson, W. L., Doyle K., Olliaro, P., Crump, J. A., & Rubach, M. P (2020). Sensitivity of C-reactive Protein for the Identification of Patients with Laboratory-Confirmed Bacterial Infections in Northern Tanzania. Tropical medicine & international health, 25(3), 291 - 300.
  7. Doyle K, Strathmann F (2017). Cost and Efficacy Assessment of an Alternative Medication Compliance Urine Drug Testing Strategy. Pain medicine (Malden, Mass.), 18(2), 307-315.
  8. Gupta S, Doyle K, Mosbruger TL, Butterfield A, Weston A, Ast A, Kaadige M, Verma A, Sharma (2018). Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells. Oncotarget, 9(11), 9907-9924.
  9. Kroner GM, Johnson-Davis KL, Doyle K, McMillin G (2020). Cannabinol (CBN) Cross-Reacts with Two Urine Immunoassays Designed to Detect Tetrahydrocannabinol (THC) Metabolite. The journal of applied laboratory medicine, 5(3), 569-574.
  10. Nelson HA, La'ulu S, Lu J, Doyle (2022). Mitigation of Biotin Interference in Manual and Automated Immunoassays by Pre-Conjugating Biotinylated Antibodies to the Streptavidin Surface as an Alternative to Biotin Depletion. The journal of applied laboratory medicine, 7(3), 762-775.
  11. Natali R, Wand C, Doyle K, Noguez J (2018). Evaluation of a new venous catheter blood draw device and its impact on specimen hemolysis rates. Practical laboratory medicine, 10, 38-43.
  12. Zilka S, Wei R, Payto D, Doyle K, Hockings J, Colón-Franco JM (2024). Measurement of Glucose 6-Phosphate Dehydrogenase (G6PD) Activity Using a Fully Automated Assay: Analytical and Operational Considerations. American journal of clinical pathology, 163(1), 153-160.
  13. Allison TR, La'ulu SL, Doyle K, Nelson H (2025). Evaluation of preanalytical factors on quantification of amyloid-ß (1-42), phosphorylated tau 181, and total tau in cerebrospinal fluid. Laboratory medicine,
  14. Saadalla A, Doyle K, Moser K, Smock (2025). Determination of Fibrinogen Ratio Cutoff Limits Using Indirect Reference Interval Methodology. International journal of laboratory hematology, 47(6), 1171-1177.
  15. Nelson HA, Condie C, Doyle K, Rudolf JW, Pearson L (2025). On-Cell Stability of Digoxin, Lithium, Phenytoin, Valproic Acid, and Vancomycin for Therapeutic Drug Monitoring. The journal of applied laboratory medicine, 10(5), 1285-1291.
  16. Nelson HA, Doyle K, Straseski J (2025). TSH Receptor Antibody Test Utilization Patterns from a National Reference Laboratory: TRAb, TSI, or Both?. The Journal of clinical endocrinology and metabolism,
  17. Bahr TM, Doyle K, Ohls RK, Christensen R (2025). Using the refineR algorithm to generate indirect reference intervals for newborn infants for the parameters "Micro-R" and "HYPO-He". Journal of perinatology,
  18. Zilka S, Wei R, Payto D, Doyle K, Hockings J, Colón-Franco J (2025). Analytical and operational considerations of measuring glucose 6-phosphate dehydrogenase (G6PD) activity using a fully automated assay. American journal of clinical pathology, 163(1), 153-160.
  19. Mathewson NJ, Pearson LN, Doyle (2023). Abnormal Hb A1c Result from a Diabetic Patient Leads to Unexpected Diagnosis. Clinical chemistry, 69(7), 684-687.
  20. Ammer T, Schützenmeister A, Rank CM, Doyle (2023). Estimation of Reference Intervals from Routine Data Using the refineR Algorithm-A Practical Guide. The journal of applied laboratory medicine, 8(1), 84-91.
  21. Erickson JA, Chiang FI, Walker CM, Genzen JR, Doyle (2022). Comparison of two chromogranin A assays and investigation of nonlinear specimens. Practical laboratory medicine, 32, e00299.
  22. Nelson HA, La'ulu SL, Lu J, Doyle (2022). Mitigation of Biotin Interference in Manual and Automated Immunoassays by Preconjugating Biotinylated Antibodies to the Streptavidin Surface as an Alternative to Biotin Depletion. The journal of applied laboratory medicine, 7(3), 762-775.
  23. Doyle K, Frank E (2021). Verifying Clinically Derived Reference Intervals for Daily Excretion Rates of Fractionated Metanephrines Using Modern Indirect Reference Interval Models. American journal of clinical pathology, 156(4), 691-699.
  24. Doyle (2021). Commentary on Extreme Hyperglycemia in an Elderly Patient. Clinical chemistry, 67(5), 729.

Review

  1. Johnson-Davis KL, Doyle (2020). Therapeutic Drug Monitoring in Pregnant Patients. Therapeutic drug monitoring, 42(2), 172-180.
  2. Doyle K, Bunch D (2023). Reference intervals: past, present, and future. Critical reviews in clinical laboratory sciences, 60(6), 466-482.
  3. Kushnir MM, Nelson HA, Doyle (2022). Clinical Utility and Analytical Aspects of Direct Measurements of Free Hormones Using Mass Spectrometry-Based Methods. The journal of applied laboratory medicine, 7(4), 945-970.

Commentary

  1. Doyle K (2021). Commentary on Extreme Hyperglycemia in an Elderly Patient. Clin Chem, 67(5), 729.

Other

  1. Doyle K (2018). Parkin Function in Parkinson's Disease. Clin Chem (64(11), p. 1676).